AstraZeneca Pharma Share Price Rises Over 1% as CDSCO Approves Cancer Drug

AstraZeneca Pharma India’s share price traded at ₹6,943.05 at 10:20 AM on the NSE, reflecting a gain of 1.24% (₹84.85) from its previous close of ₹6,858.20.

The stock opened at ₹6,868.25 and reached an intraday high of ₹6,957.85, while the lowest price recorded during the session so far was ₹6,730.05.

Key Details of the Approval

AstraZeneca Pharma India has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab solutions, a key drug used in cancer treatment.

This approval marks a significant step toward expanding treatment options for patients with unresectable hepatocellular carcinoma (uHCC) in India.

The drug, in combination with Tremelimumab, is intended for treating uHCC, a severe form of liver cancer that cannot be surgically removed.

While the approval allows the import and distribution of Durvalumab, the marketing of the drug remains subject to additional statutory clearances.

Impact on Cancer Treatment in India

The approval of Durvalumab in combination with Tremelimumab is a significant development for cancer care in India.

Hepatocellular carcinoma is one of the most common types of liver cancer, and treatment options remain limited. With this approval, AstraZeneca is set to provide advanced immunotherapy solutions, potentially improving survival rates and quality of life for affected patients.

AstraZeneca’s Commitment to Oncology

AstraZeneca continues to strengthen its oncology portfolio in India, focusing on introducing innovative treatments for critical diseases. The approval of Durvalumab aligns with the company’s mission to make advanced cancer therapies accessible to patients across the country.

Conclusion

The CDSCO’s approval for Durvalumab solutions marks a crucial milestone in expanding cancer treatment options in India. As AstraZeneca Pharma India moves forward with the import and distribution process, this development underscores the growing focus on immunotherapy and targeted treatments in the country’s healthcare landscape.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.